Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3
摘要:
A novel series of 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitors has been identified. These inhibitors, based on a dibenzazocine core, exhibited picomolar to low nanomolar inhibition of 17 beta-HSD3 in cell-free enzymatic as well as in cell-based transcriptional reporter assays. (C) 2005 Elsevier Ltd. All rights reserved.
TRICYCLIC PYRAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS
申请人:Abbott GmbH & Co. KG
公开号:EP1289525A2
公开(公告)日:2003-03-12
US6462036B1
申请人:——
公开号:US6462036B1
公开(公告)日:2002-10-08
[EN] TRICYCLIC PYRAZOLE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLE TRICYCLIQUE
申请人:BASF AG
公开号:WO2000027822A2
公开(公告)日:2000-05-18
This invention relates to certain 3-aryl or 3-heteroaryl pyrazoles with 4,5(3,4)-bicyclic ring fusion which are inhibitors of protein kinase activity, of which some are novel compounds, to pharmaceutical compositions containing these pyrazoles and to processes for preparing these pyrazoles.
[DE] BET-PROTEININHIBITORISCHE 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONE MIT META-SUBSTITUIERTER AROMATISCHER AMINO- ODER ETHERGRUPPE<br/>[EN] BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS<br/>[FR] 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES INHIBITRICES DE PROTÉINE BET, À GROUPE ÉTHER OU AMINO AROMATIQUE META-SUBSTITUÉ
申请人:BAYER PHARMA AG
公开号:WO2015193229A1
公开(公告)日:2015-12-23
Die vorliegende Erfindung betrifft BET-proteininhibitorische 1,4-Dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer Amino- oder Ethergruppe der allgemeinen Formeln (I) und (Ia) in denen A, X, Y, R1, R2, R3, R4, R5, R6 und n die in der Beschreibung angegebenen Bedeutungen haben, pharmazeutische Mittel enthaltend die erfindungsgemäßen Verbindungen sowie deren prophylaktische und therapeutische Verwendung bei hyper-proliferativen Erkrankungen, insbesondere bei Tumorerkrankungen. Desweiteren betrifft diese Erfindung die Verwendung von BET-Proteininhibitoren in viralen Infektionen, in neurodegenerativen Erkrankungen, in inflammatorischen Krankheiten, in atherosklerotischen Erkrankungen und in der männlichen Fertilitätskontrolle.